Class Action Lawsuit Announced Against Erasca, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, alleging violations of federal securities laws by the company and its executives, which resulted in investor losses.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected parties to join the action.
- False Statements Allegation: The lawsuit claims that Erasca misrepresented its oncology drug candidate ERAS-0015, failing to disclose improper comparisons with a competitor's drug, leading to significant investor losses when the truth emerged, thereby damaging the company's reputation and market trust.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 19.180
Low
2.00
Averages
5.50
High
11.00
Current: 19.180
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Erasca, Inc. Shareholder Class Action Reminder
- Class Action Initiated: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed to protect investor rights and seek recovery of losses.
- Patent Risk Disclosure: The lawsuit alleges that Erasca failed to disclose its risk of infringing patent and trade secret protections, particularly regarding ERAS-0015's preclinical data, which was claimed to be improperly compared to data from Revolution Medicines, Inc., undermining the validity of the company's positive statements.
- Stock Price Impact: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price plummeted from $21.49 per share on April 24, 2026, to $19.15, indicating the market's sensitive reaction to the company's legal risks.
- Shareholder Action Guidance: Shareholders can submit their applications by August 10, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in the company's future.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses due to misleading information.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which could adversely affect the market outlook for its product.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, market reactions intensified, raising serious concerns about the safety profile of the product and potentially impacting future clinical trials and regulatory approvals.
See More
Class Action Reminder for Erasca, Inc. Shareholders
- Lawsuit Background: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed, alleging the company failed to disclose risks related to patent and trade secret protections.
- Allegation Details: The complaint states that during the class period, Erasca did not disclose that the preclinical data for ERAS-0015 was based on improper comparisons, potentially leading to patent and trade secret violations, and lacked a reasonable basis for its positive statements regarding ERAS-0015.
- Stock Price Impact: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price fell from $21.49 per share on April 24, 2026, to $19.15 per share, reflecting market concerns about the company's future.
- Shareholder Action Advice: Shareholders may submit their papers to become lead plaintiffs in the class action by August 10, 2026, with lead plaintiffs representing other members in directing the litigation, while absent members can still be eligible for recovery.
See More
Embecta, Erasca, Hub Group, and ZoomInfo Under Investigation for Fiduciary Breaches
- Investigation Background: Grabar Law Office is investigating whether certain officers of Embecta Corp. breached their fiduciary duties, particularly regarding oversight of business operations and internal controls, potentially leading shareholders to seek governance reforms and fund recovery.
- Declining Financial Performance: Embecta's Q2 2026 results significantly missed expectations, with revenue declining sharply due to weakness in the U.S. market and adverse market dynamics, causing the stock price to plummet over 57% in a single day from $9.25 to $3.90.
- Erasca's Risks: Erasca faces allegations of misleading statements regarding its drug candidate ERAS-0015, with investors not adequately informed of associated intellectual property risks, which could expose the company to legal liabilities and shareholder claims.
- ZoomInfo's False Statements: ZoomInfo is accused of making false and misleading statements in its financial guidance, failing to disclose deterioration in its core business, severely undermining investor confidence in the company's future growth prospects.
See More
Erasca Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for violations of securities laws, involving securities transactions from January 14, 2025, to April 26, 2026, with a deadline for investor contact set for August 10, 2026.
- False Statement Allegations: The complaint alleges that Erasca made misleading statements regarding its ERAS-0015 preclinical data, which was improperly compared to Revolution Medicines, leading to unfounded optimistic claims and exposing investors to potential losses.
- Market Reaction: As the market became aware of the true situation regarding Erasca, investors suffered damages, highlighting significant failures in the company's disclosure practices that could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to understand their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Erasca Shareholder Class Action Notice
- Class Action Deadline: Shareholders of Erasca, Inc. (NASDAQ: ERAS) must apply to be lead plaintiffs by August 10, 2026, to participate in a class action lawsuit against the company and its executives, potentially receiving compensation without any out-of-pocket costs.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its oncology drug candidate ERAS-0015 from January 14, 2025, to April 26, 2026, claiming it was a 'best-in-class' therapy while failing to disclose improper comparisons that led to investor losses.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong expertise and successful track record in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Erasca, Inc. Shareholder Class Action Reminder
- Class Action Initiated: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed to protect investor rights and seek recovery of losses.
- Patent Risk Disclosure: The lawsuit alleges that Erasca failed to disclose its risk of infringing patent and trade secret protections, particularly regarding ERAS-0015's preclinical data, which was claimed to be improperly compared to data from Revolution Medicines, Inc., undermining the validity of the company's positive statements.
- Stock Price Impact: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price plummeted from $21.49 per share on April 24, 2026, to $19.15, indicating the market's sensitive reaction to the company's legal risks.
- Shareholder Action Guidance: Shareholders can submit their applications by August 10, 2026, to serve as lead plaintiffs in the class action, representing other shareholders in the litigation, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
Erasca Faces Securities Class Action After Patent Infringement Claims
- Stock Price Plunge: Erasca's stock plummeted by $9.25 (-48%) following accusations of patent infringement from Revolution Medicines, resulting in a loss of over $2.8 billion in market capitalization, indicating a severe erosion of investor confidence in the company's future.
- Lawsuit Initiation: Hagens Berman has filed a securities class action against Erasca, alleging that the company misled investors between January 14, 2025, and April 26, 2026, potentially exposing investors to significant losses due to misleading information.
- Intellectual Property Dispute: Erasca is accused of improperly comparing its ERAS-0015 to RevMed's RMC-6236 without disclosing potential intellectual property disputes, which could adversely affect the market outlook for its product.
- Patient Adverse Event: Following the disclosure of a patient's death one month after receiving ERAS-0015, market reactions intensified, raising serious concerns about the safety profile of the product and potentially impacting future clinical trials and regulatory approvals.
See More
Class Action Reminder for Erasca, Inc. Shareholders
- Lawsuit Background: Robbins LLP reminds all shareholders who purchased Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025, and April 26, 2026, that a class action has been filed, alleging the company failed to disclose risks related to patent and trade secret protections.
- Allegation Details: The complaint states that during the class period, Erasca did not disclose that the preclinical data for ERAS-0015 was based on improper comparisons, potentially leading to patent and trade secret violations, and lacked a reasonable basis for its positive statements regarding ERAS-0015.
- Stock Price Impact: Following the disclosure of a legal letter from RevMed on April 27, 2026, Erasca's stock price fell from $21.49 per share on April 24, 2026, to $19.15 per share, reflecting market concerns about the company's future.
- Shareholder Action Advice: Shareholders may submit their papers to become lead plaintiffs in the class action by August 10, 2026, with lead plaintiffs representing other members in directing the litigation, while absent members can still be eligible for recovery.
See More
Embecta, Erasca, Hub Group, and ZoomInfo Under Investigation for Fiduciary Breaches
- Investigation Background: Grabar Law Office is investigating whether certain officers of Embecta Corp. breached their fiduciary duties, particularly regarding oversight of business operations and internal controls, potentially leading shareholders to seek governance reforms and fund recovery.
- Declining Financial Performance: Embecta's Q2 2026 results significantly missed expectations, with revenue declining sharply due to weakness in the U.S. market and adverse market dynamics, causing the stock price to plummet over 57% in a single day from $9.25 to $3.90.
- Erasca's Risks: Erasca faces allegations of misleading statements regarding its drug candidate ERAS-0015, with investors not adequately informed of associated intellectual property risks, which could expose the company to legal liabilities and shareholder claims.
- ZoomInfo's False Statements: ZoomInfo is accused of making false and misleading statements in its financial guidance, failing to disclose deterioration in its core business, severely undermining investor confidence in the company's future growth prospects.
See More
Erasca Faces Class Action Lawsuit Reminder for Investors
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Erasca, Inc. for violations of securities laws, involving securities transactions from January 14, 2025, to April 26, 2026, with a deadline for investor contact set for August 10, 2026.
- False Statement Allegations: The complaint alleges that Erasca made misleading statements regarding its ERAS-0015 preclinical data, which was improperly compared to Revolution Medicines, leading to unfounded optimistic claims and exposing investors to potential losses.
- Market Reaction: As the market became aware of the true situation regarding Erasca, investors suffered damages, highlighting significant failures in the company's disclosure practices that could adversely affect its future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations, encouraging affected investors to reach out to understand their rights, demonstrating the firm's commitment to supporting investor interests.
See More
Erasca Shareholder Class Action Notice
- Class Action Deadline: Shareholders of Erasca, Inc. (NASDAQ: ERAS) must apply to be lead plaintiffs by August 10, 2026, to participate in a class action lawsuit against the company and its executives, potentially receiving compensation without any out-of-pocket costs.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, made false and misleading statements about its oncology drug candidate ERAS-0015 from January 14, 2025, to April 26, 2026, claiming it was a 'best-in-class' therapy while failing to disclose improper comparisons that led to investor losses.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong expertise and successful track record in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
